MX2008009830A - Efecto del inhibidor bst2. - Google Patents

Efecto del inhibidor bst2.

Info

Publication number
MX2008009830A
MX2008009830A MX2008009830A MX2008009830A MX2008009830A MX 2008009830 A MX2008009830 A MX 2008009830A MX 2008009830 A MX2008009830 A MX 2008009830A MX 2008009830 A MX2008009830 A MX 2008009830A MX 2008009830 A MX2008009830 A MX 2008009830A
Authority
MX
Mexico
Prior art keywords
bst2
inhibitor
cells
immune cells
binding
Prior art date
Application number
MX2008009830A
Other languages
English (en)
Inventor
Sang-Ho Park
Myung Kim
Jay Chung
June-Young Park
Hyouna Yoo
Sang-Min Lee
Yoon-Seok Lee
Mison Koo
Juheng Lee
Young Mi Hur
Original Assignee
Isu Abxis Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/471,853 external-priority patent/US7740856B2/en
Priority claimed from US11/757,329 external-priority patent/US20080299128A1/en
Application filed by Isu Abxis Co Ltd filed Critical Isu Abxis Co Ltd
Publication of MX2008009830A publication Critical patent/MX2008009830A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La solicitud describe un método para impedir que células inmunitarias se unan a otras células, que incluye poner en contacto las células inmunitarias y las otras células con una composición que comprende el antagonista de Bst2.
MX2008009830A 2006-06-20 2007-06-20 Efecto del inhibidor bst2. MX2008009830A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/471,853 US7740856B2 (en) 2005-12-20 2006-06-20 Effect of BST2 on inflammation
US11/757,329 US20080299128A1 (en) 2006-06-20 2007-06-01 Effect of Bst2 on inflammation
PCT/US2007/014434 WO2008127261A1 (en) 2006-06-20 2007-06-20 Bst2 inhibitor

Publications (1)

Publication Number Publication Date
MX2008009830A true MX2008009830A (es) 2009-05-11

Family

ID=41050321

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008009830A MX2008009830A (es) 2006-06-20 2007-06-20 Efecto del inhibidor bst2.

Country Status (7)

Country Link
JP (1) JP2009536952A (es)
KR (1) KR20110029181A (es)
CN (1) CN101516910A (es)
BR (1) BRPI0708042A2 (es)
IL (1) IL193143A0 (es)
MX (1) MX2008009830A (es)
RU (1) RU2419629C2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014142433A1 (ko) * 2013-03-13 2014-09-18 고려대학교산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
KR20140112255A (ko) 2013-03-13 2014-09-23 고려대학교 산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
KR101678666B1 (ko) * 2014-09-02 2016-11-23 주식회사 이뮤노맥스 Bst2 유전자의 기능이 상실된 세포주를 이용한 바이러스 감염 증진방법
US10526393B2 (en) 2014-06-18 2020-01-07 Immunomax Co., Ltd. Method for promoting virus infection and increasing virus production, by using cell line having lost BST2 gene functions
CN107619438B (zh) * 2017-10-11 2021-12-03 广州云启科技有限公司 新型环二核苷酸受体及其激动剂或抑制剂筛选的方法和试剂盒
CN109481685B (zh) * 2019-01-11 2021-05-14 深圳先进技术研究院 Cd317抑制剂在制备治疗肝癌的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
DE19647382A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
US20020034507A1 (en) * 1997-02-28 2002-03-21 Yasuo Koishihara Inhibitor of lymphocyte activation
JP3552898B2 (ja) * 1997-02-28 2004-08-11 中外製薬株式会社 リンパ球の活性化抑制剤
JP2003219894A (ja) * 1998-02-25 2003-08-05 Chugai Pharmaceut Co Ltd Ｈｍ１．２４抗原タンパク質をコードするゲノム遺伝子及びそのプロモーター
JP2002338599A (ja) * 2000-12-27 2002-11-27 Sankyo Co Ltd 血中滞留性が向上した生理活性タンパク質およびその調製方法

Also Published As

Publication number Publication date
JP2009536952A (ja) 2009-10-22
RU2008131538A (ru) 2010-02-10
RU2419629C2 (ru) 2011-05-27
KR20110029181A (ko) 2011-03-22
CN101516910A (zh) 2009-08-26
BRPI0708042A2 (pt) 2011-05-17
IL193143A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
WO2009149956A3 (en) Fusion protein and use thereof
WO2011031896A3 (en) Pi3 kinase inhibitors and uses thereof
WO2011113798A3 (en) Inhibitors of semicarabazide - sensitive amine oxidase
WO2008060705A3 (en) Anti-dll4 antibodies and methods using same
WO2008073483A3 (en) Methods and systems related to receiving nutraceutical associated information
FR2883179B1 (fr) Comprime enrobe
TW200732349A (en) Anti-OX40L antibodies and methods using same
IL211284A0 (en) Antibodies binding ccr2, compositions comprising the same and uses thereof
WO2008085570A3 (en) Flux formulations
PL2126020T3 (pl) Hydrofobowo modyfikowane polialkilenoiminy jako inhibitory przenoszenia barwnika
WO2010006173A3 (en) Mineral amino acid polysaccharide complex
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
MX2011006254A (es) Composiciones aclaradoras de la piel con inhibidores de acetilcolinesterasa.
WO2008070616A3 (en) METHODS AND COMPOSITIONS RELATED TO HIF-1α
TN2009000151A1 (en) Mapk/erk kinase inhibitors
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
GB0601143D0 (en) Uses, methods and compositions
WO2008011433A3 (en) Styrenated terpene resin as well as methods of making and using the same
MX2008009830A (es) Efecto del inhibidor bst2.
WO2007146813A3 (en) Pyridinone analogs as cell proliferation inhibitors
WO2011140334A3 (en) Compounds, methods of making or identifying compounds, and uses thereof
WO2007148102A3 (en) Crystalline duloxetine hydrochloride
MX2007002917A (es) Todo-trans-retinol: todo-trans-13, 14-dihidrorretinol saturasa y metodos de uso de la misma.
WO2010077317A3 (en) Protease inhibitors

Legal Events

Date Code Title Description
FG Grant or registration